Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1107
Abstract: Intravenous (IV) drug administration enables treatment of epilepsy when oral administration is temporarily not feasible. Perampanel is a once‐daily antiseizure medication currently available as oral formulations. Study 050 (NCT03376997) was an open‐label, randomized, single‐dose, crossover… read more here.
Keywords: safety; oral perampanel; alternative oral; perampanel ... See more keywords
Therapeutic drug monitoring of perampanel in children diagnosed with epilepsy: Focus on influencing factors on the plasma concentration‐to‐dose ratio
Sign Up to like & getrecommendations! Published in 2022 at "Epilepsia Open"
DOI: 10.1002/epi4.12653
Abstract: This study aimed to investigate the efficacy and tolerability of perampanel (PER) therapy and to optimize a specific plasma reference range for PER in children. Another major aim was to evaluate the potential determinators of… read more here.
Keywords: monitoring perampanel; therapeutic drug; concentration; perampanel children ... See more keywords
Real‐world use of adjunctive perampanel for focal‐onset seizures in Italy: A mirroring clinical practice study of perampanel in adults and adolescents (AMPA)
Sign Up to like & getrecommendations! Published in 2025 at "Epilepsia Open"
DOI: 10.1002/epi4.70068
Abstract: The AMPA study (Study 501; NCT04257604) was a multicenter, prospective, 12‐month observational study in Italy that evaluated the effectiveness and safety of adjunctive perampanel in patients with focal‐onset seizures (FOS), with or without focal to… read more here.
Keywords: focal onset; perampanel; onset seizures; study ... See more keywords
Efficacy and safety of perampanel in refractory and super-refractory status epilepticus: cohort study of 81 patients and literature review
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Neurology"
DOI: 10.1007/s00415-021-10506-9
Abstract: The effective dose of perampanel in status epilepticus (SE), refractory SE (RSE), and super-refractory SE (SRSE) in humans is unknown, and the potential of perampanel in treating SE has not been evaluated in a large… read more here.
Keywords: status epilepticus; refractory; perampanel; super refractory ... See more keywords
Intrathecally administered perampanel alleviates neuropathic and inflammatory pain in rats.
Sign Up to like & getrecommendations! Published in 2020 at "European journal of pharmacology"
DOI: 10.1016/j.ejphar.2020.172949
Abstract: Chronic pain conditions such as neuropathic pain and persistent inflammatory pain are difficult to manage. Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors modulate nociceptive processing at the spinal dorsal horn. Previous studies have shown that intrathecal AMPA receptor… read more here.
Keywords: neuropathic inflammatory; inflammatory pain; pain; ampa receptor ... See more keywords
The anxiolytic effect of perampanel and possible mechanisms mediating its anxiolytic effect in mice.
Sign Up to like & getrecommendations! Published in 2020 at "Life sciences"
DOI: 10.1016/j.lfs.2020.118359
Abstract: AIMS The aim of this study is to investigate the anxiolytic activity of perampanel, a non-competitive antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type glutamate receptors, which is approved for partial-onset seizures in patients with epilepsy, and… read more here.
Keywords: effect perampanel; effect; perampanel; anxiolytic activity ... See more keywords
A Liquid Chromatography-Mass Spectrometry Assay for Determination of Perampanel and Concomitant Antiepileptic Drugs in the Plasma of Patients With Epilepsy Compared With a Fluorescent HPLC Assay
Sign Up to like & getrecommendations! Published in 2018 at "Therapeutic Drug Monitoring"
DOI: 10.1097/ftd.0000000000000531
Abstract: Background: Perampanel is a novel noncompetitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid (AMPA) glutamate receptor, which is approved as an adjunctive agent for the treatment of partial-onset seizure with or without secondary generalization… read more here.
Keywords: mass spectrometry; chromatography mass; liquid chromatography; patients epilepsy ... See more keywords
Effectiveness and safety of perampanel in adults with mesial temporal epilepsy
Sign Up to like & getrecommendations! Published in 2019 at "Medicine"
DOI: 10.1097/md.0000000000017171
Abstract: Abstract Mesial temporal lobe epilepsy (MTLE) is a common epilepsy syndrome often refractory to antiepileptic drug (AED) treatment. The purpose of this study was to evaluate the effectiveness and tolerability of perampanel (PER) as add-on… read more here.
Keywords: mesial temporal; treatment; epilepsy; seizure ... See more keywords
Effectiveness and tolerability of adjunctive perampanel in pediatric patients (aged 4–12 years) with refractory epilepsy: An observational study
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031408
Abstract: Information on the effects of perampanel in Chinese children ≤12 years of age with refractory epilepsy is limited; thus, we conducted an observational study to assess the effectiveness, safety, and tolerability of adjunctive perampanel in… read more here.
Keywords: patients aged; refractory epilepsy; aged years; perampanel ... See more keywords
Pharmacokinetic/pharmacodynamic analysis of adjunctive perampanel in subjects with partial‐onset seizures
Sign Up to like & getrecommendations! Published in 2018 at "Acta Neurologica Scandinavica"
DOI: 10.1111/ane.12874
Abstract: Explore perampanel pharmacokinetics (PK) in all subjects (aged ≥12 years) vs adolescents (aged ≥12 to ≤17 years) with partial‐onset seizures (POS) and identify factors explaining between‐subject variability in efficacy using a population PK/pharmacodynamic (PD) analysis. read more here.
Keywords: partial onset; perampanel; pharmacodynamic analysis; onset seizures ... See more keywords
PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma
Sign Up to like & getrecommendations! Published in 2024 at "BMC Cancer"
DOI: 10.1186/s12885-024-11846-1
Abstract: Glioblastoma is the most frequent and a particularly malignant primary brain tumor with no efficacy-proven standard therapy for recurrence. It has recently been discovered that excitatory synapses of the AMPA-receptor subtype form between non-malignant brain… read more here.
Keywords: treatment; trial; persurge; perampanel ... See more keywords